title: The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
abstract: Hyperphosphatemia is a risk factor for arterial calcification contributing to the high-cardiovascular mortality in patients with chronic kidney disease (CKD). Ferric citrate hydrate (JTT-751) is being developed as a treatment for hyperphosphatemia with chronic renal failure and has shown a serum phosphorus-lowering effect in CKD patients. In this study, we evaluated the combination effect of JTT-751 with the phosphorus absorption-reducing effect of calcium carbonate and compared phosphorus absorption-reducing efficacy between three phosphate binders including JTT-751. Normal rats were fed a diet containing either 1% calcium carbonate, 1% JTT-751 or 1% JTT-751 with 1% calcium carbonate, for 7 days. Both 1% calcium carbonate and 1% JTT-751 alone reduced urinary phosphorus excretion, and the combined treatment reduced it more than each single-treatment, without clearly influencing calcium or iron-metabolism. Next, normal rats were fed a diet containing either 0.3, 1 and 3% lanthanum carbonate or 2.3% JTT-751, for 7 days. Either 3% lanthanum carbonate or 2.3% JTT-751 reduced urinary phosphorus excretion. Finally, we compared the reduced amount of urinary phosphorus excretion per dose of compound, of which JTT-751 is comparable to that of calcium carbonate and is greater than that of the lanthanum carbonate. In conclusion, JTT-751 showed an additive effect on the phosphorus absorption-reducing effect of calcium carbonate without influencing calcium- and iron-metabolism, and had a phosphorus absorption-reducing efficacy comparable to or greater than other existing phosphate binders.
authors: Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute , Japan Tobacco Inc., Osaka , Japan and.
authors: Akira
authors: A
authors: Matsuo
authors: Akio
authors: A
authors: Iida
authors: Minako
authors: M
authors: Tanimoto
authors: Mutsuyoshi
authors: M
authors: Matsushita
authors: Ken-ichi
authors: K
authors: Miyamoto
mesh_terms: D000818:Animals; D002119:Calcium Carbonate / Q000494:pharmacology*; D005290:Ferric Compounds / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects; D007811:Lanthanum / Q000494:pharmacology*; D008297:Male; D010758:Phosphorus / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D005290:Ferric Compounds; D010758:Phosphorus; C119467:lanthanum carbonate; C025314:ferric citrate; D007811:Lanthanum; D002119:Calcium Carbonate
keywords: Combined treatment; comparison of efficacy; ferric citrate hydrate; phosphate binder; phosphorus absorption